Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far
This article was originally published in The Pink Sheet Daily
Executive Summary
All five biosimilars in Pfizer’s clinical pipeline overlap with those in Hospira’s, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.